약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

Alzheimer’s Disease treatments included in the analysis

Donepezil Galantamine Rivastigmine Memantine
Marketed date 2000/04 2004/09 2000/10 2003/09
Entry date of generics 2008/12 2009/11 2014/09 2012/04
Formulation Tablet, ODF Sustained Release tablet, Sustained Release capsule Capsule, Patch, ,Liquid Tablet, ODT
DDD 7.5 mg 16 mg 9 mg 20 mg
Criteria for NHI funding Mild, moderate, severe AD Mild-moderate AD Mild-moderate AD Moderate-severe AD
MMSE score MMSE≤26 10≤MMSE≤26 10≤MMSE≤26 MMSE≤20
Cost ratio (2018yr) 80.3% 3.5% 5.1% 11.1%
DDD ratio (2018yr) 75.8% 2.7% 5.4% 16.1%

Note: ODF: Oral Dissolving Film, ODT: Oral Dissolving Tablet, NHI: National Health Insurance, AD: Alzheimer’s Dementia, MMSE: Mini-Mental State Examination

Yakhak Hoeji 2022;66:58-65 https://doi.org/10.17480/psk.2022.66.2.58
© 2022 Yakhak Hoeji